查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
生育药物市场规模份额和趋势分析报告:按药物(促性腺激素,芳香□抑製剂,SERM,多巴胺激动剂),用途(男性,女性),分销渠道,地区,细分市场预测2023～2030
市场调查报告书
商品编码
1178624

生育药物市场规模份额和趋势分析报告:按药物(促性腺激素,芳香□抑製剂,SERM,多巴胺激动剂),用途(男性,女性),分销渠道,地区,细分市场预测2023～2030

Infertility Drugs Market Size, Share & Trends Analysis Report By Drug Class (Gonadotropins, Aromatase Inhibitors, SERMs, Dopamine Agonists) By End-user (Men, Women), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10个工作天内

价格

生育药物市场的增长和趋势

根据 Grand View Research, Inc. 的最新报告，2023 年至 2030 年，全球生育药物市场预计将以 6.1% 的复合年增长率增长，2030 年将达到 56 亿美元。市场已经饱和，新进入者的机会很少。Merck & Co. Inc.、Ferring BV 和 Organon 集团公司占据了该市场的大部分市场份额。因此，药企纷纷着力开发促性腺激素生物类似药，以开拓市场。例如，齐鲁製药重点研发重组人促卵泡激素QL1012，目前正在进行3期临床试验。成功完成临床试验并随后上市有望引领市场。

公共和私人机构越来越多地帮助不孕症患者，预计将对生育治疗市场的增长产生积极影响。例如，法国政府于2022年3月出台了体外受精法，允许单身女性和同性伴侣在该国的国家医疗体系下接受免费治疗。

同样在 2022 年 11 月，沙特健康保险委员会进行了一项关于将药物纳入医疗保险范围的研究。这项研究的成功和药物的报销范围将改善患者获得治疗的机会，随后，预计在预测期内对该药物的需求将会增加。

患者和医生对疾病和可用药物的认识不断提高，预计将增加市场的目标人群。例如，2021 年 9 月，Mubadala Health 和 United Eastern Medical Services (UEMedical) 将在迪拜推出“第三方”，旨在提高医生和患者对这种疾病治疗进展及其益处的认识。加上中东不孕症会议。

此外，由于政府努力应对少子化和促进生育，对药物的需求可能会增加。例如，2022 年 8 月，韩国政府宣布了一项规定，为每个新生儿的家庭每月支付 740 美元，旨在解决该国出生率下降的问题并鼓励更多的生育。

生育药物市场报告要点

按药物类别划分，促性腺激素部分预计将在 2022 年占据最大的市场份额，并在预测期内增长最快。这是由于市场上有 FDA 批准的用于治疗不孕症的促性腺激素。

从最终用途来看，由于 PCOS、HPV 相关阴道癌和子宫肌瘤等女性疾病发病率上升，2022 年女性市场将主导生育市场。2022 年 4 月，一项队列研究宣布，约 1.5% 的 20-49 岁法国女性将被诊断患有不孕症。

2022 年的生育药物市场由医院药房板块主导。这种增长可能是由于全球范围内因诊断和治疗这种疾病而入院的人数增加。

北美在 2022 年主导了全球市场，原因包括医疗保健专业人员对不孕症的认识提高、药物供应以及疾病流行率上升等因素。

目录

第一章 调查方法和范围

  • 市场细分和范围
    • 段范围
    • 区域范围
  • 调查方法
  • 信息采购
    • 购买的数据库：
    • GVR 内部数据库
    • 次要信息
    • 初步调查
    • 第一次调查的内容
  • 信息或数据分析
    • 数据分析模型
  • 市场製定和验证
  • 型号详情
    • 商品流向分析
      • 方法：产品流方法
  • 调查假设
  • 二级信息列表
  • 缩略语表
  • 目的

第二章执行摘要

  • 市场快照
  • 段快照
  • 争用快照

3 生育药物：市场变量、趋势和范围

  • 市场系列展望
    • 女性健康市场
  • 绘製渗透率和增长前景
  • 监管状况
  • 市场动态
  • 市场驱动力分析
    • 增加不孕负担
    • 存在强大的产品线
    • 增加不孕不育研究和开发的资金
  • 市场约束因素分析
    • 不合作的政府对生育药物的监管
  • PESTEL 分析
  • 行业分析——波特五力
  • 管道分析

4 生育药物市场：细分分析，按药物类别，2018-2030 年（百万美元）

  • 生育药物市场：药物类别的变化分析
  • 促性腺激素
    • 芳香□抑製剂
    • 选择性雌激素受体调节剂 (SERM)
    • 多巴胺激动剂
    • 其他

5 生育药物市场：细分分析，按分销渠道，2018-2030 年（百万美元）

  • 生育药物市场：分销渠道波动分析
  • 医院药房
  • 专业和零售药店
  • 网上药店

6. 生育药物市场：细分分析，按最终用途，2018-2030 年（百万美元）

  • 生育药物市场：最终用户差异分析
  • 男性
  • 女士

第七章生育药物市场：区域估计和趋势分析

  • 北美
    • SWOT分析：
    • 美国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 加拿大
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
  • 欧洲
    • SWOT分析：
    • 英国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
      • 处方和配药场景
    • 德国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 法国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 意大利
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 西班牙
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 丹麦
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 瑞典
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 挪威
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
  • 亚太地区
    • SWOT分析：
    • 日本
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
      • 处方和配药场景
    • 中国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 印度
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 澳大利亚
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 韩国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 泰国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
  • 拉丁美洲
    • SWOT分析：
    • 巴西
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
      • 处方和配药场景
    • 墨西哥
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 阿根廷
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
  • 中东和非洲 (MEA)
    • SWOT分析：
    • 南非
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
      • 处方和配药场景
    • 沙特阿拉伯
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 阿拉伯联合酋长国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景
    • 科威特
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争情景
      • 监管框架
      • 赎回场景

8 生育药物市场：竞争分析

  • 主要市场进入者的最新发展和影响分析
    • 新产品发布
    • 併购
    • 许可协议
    • 会议和活动
  • 公司分类
    • 创新者
    • 市场领导者
  • 供应商情况
    • 主要经销商及渠道合作伙伴名单
    • 主要客户
  • 上市公司
    • 2021 年主要参与者的市场份额分析
    • 公司市场分析
    • 热图分析
    • 竞争仪錶盘分析
      • 市场差异化因素
  • 民营企业
    • 主要初创企业名单
    • 区域网络图
  • 公司简介
    • Bayer AG
    • 公司简介
    • 财务绩效
    • 产品对标
    • 战略举措
  • Novartis AG
    • 公司简介
    • 财务绩效
    • 产品基准
    • 战略举措
  • Merck
    • 公司简介
    • 财务绩效
    • 产品基准
    • 战略举措
  • Ferring BV
    • 公司简介
    • 财务绩效
    • 产品基准
    • 战略举措
  • Pfizer
    • 公司简介
    • 财务绩效
    • 产品基准
    • 战略举措
  • human pharmaceutical
    • 公司简介
    • 财务绩效
    • 产品基准
    • 战略举措
  • Teva Pharmaceutical Industries Ltd.
    • 公司简介
    • 财务绩效
    • 产品基准
    • 战略举措
  • Sanofi
    • 公司简介
    • 财务绩效
    • 产品基准
    • 战略举措
  • Abbott
    • 公司简介
    • 财务绩效
    • 产品基准
    • 战略举措
  • Organon Group of Country
    • 公司简介
    • 产品基准
    • 战略举措
Product Code: GVR-4-68040-016-5

Infertility Drugs Market Growth & Trends:

The global infertility drugs market size is expected to reach USD 5.6 billion by 2030 expanding at a CAGR of 6.1% from 2023 to 2030 according to a new report by Grand View Research, Inc. The market seems to be saturated with fewer opportunities for new entrants. The companies including Merck & Co. Inc., Ferring B.V., and Organon group of companies holds majority of market share. Thus, the pharmaceutical companies are focusing on developing biosimilar of gonadotropins for market penetration. For instance, Qilu Pharmaceutical Co., Ltd. focuses on developing QL1012, a recombinant human follicle stimulating hormone which is under phase 3 clinical trial. Successful completion of of trial and subsequent launch is anticipated to drive market.

Increasing initiatives undertaken by public and private organizations to support patients living with infertility are expected to positively contribute to infertility treatment market growth. For instance, in March 2022, the French government introduced new IVF law under which single women and same sex-couple avail treatment free of cost under the country's national healthcare system.

In addition, in November 2022, Saudi Arabia's Health Insurance Council conducted studies with regard to the inclusion of medicines under medical insurance coverage. The successful completion of the study and inclusion of medication under insurance is anticipated to increase patient access to treatment, subsequently, increase demand for medicines over the forecast period.

Rising awareness about disease and its available medicines among patients and physicians is anticipated to increase the target population for the market. For instance, in September 2021, Mubadala Health and United Eastern Medical Services (UEMedical) organized the '3rd HealthPlus Middle East Fertility Conference with an aim to rise awareness about the advancements in the treatment of this conditions and its benefits among physicians and patients in Dubai.

Moreover, there are several initiatives undertaken by the national government worldwide to tackle low fertility rate issues and promote childbirth which may increase the demand for drugs. For instance, in August 2022, the South Korean Government announced a provision for a monthly allowance of USD 740 per new child born in the family with an aim to tackle the low fertility rate in the country and encourage childbirth.

Infertility Drugs Market Report Highlights:

  • By drug class, the gonadotropin segment accounted for the largest share of the market in 2022 and is anticipated to witness fastest growth over the forecast period. This can be attributed to the availability of FDA-approved gonadotropins for infertility conditions in the market
  • Based on end-user, the women segment dominated the infertility drugs market in 2022 owing to the rising incidence of the diseases such as PCOS, HPV associated vaginal cancer, uterine fibroids in women. As per the cohort studies published, in April 2022, approximately 1.5% of all French women aged 20 to 49 years were diagnosed with this condition annually.
  • Hospiatal pharmacy segment dominated the infertility drugs market in 2022. This growth can be attributed to an increase in inpatient visits for the diagnosis and consulation of this condition worldwide
  • North America dominated the global market in 2022 owing to factors such as high awareness among healthcare professionals about infertility conditions, ease of availability of drugs, and an increase in disease prevalence.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment Scope
    • 1.1.2 Regional Scope
    • 1.1.3 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database:
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation and Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach: Commodity Flow Approach
  • 1.7 Research Assumptions
  • 1.8 List of Secondary Sources
  • 1.9 List of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective 1
    • 1.10.2 Objective 2
    • 1.10.3 Objective 3
    • 1.10.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot
  • 2.3 Competitive Snapshot

Chapter 3 Infertility Drugs: Market Variables, Trends, and Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Women's Health Market
  • 3.2 Penetration and Growth Prospect Mapping
  • 3.3 Regulatory Landscape
  • 3.4 Market Dynamics
  • 3.5 Market Driver Analysis
    • 3.5.1 Rising burden of infertility
    • 3.5.2 Presence of strong product pipeline
    • 3.5.3 Increasing funding for infertility R&D
  • 3.6 Market Restraint Analysis
    • 3.6.1. Unsupportive Government Regulations for Infertility Drugs
  • 3.7 PESTEL Analysis
  • 3.8 Industry Analysis-Porter's Five Forces
  • 3.9 Pipeline Analysis

Chapter 4 Infertility Drugs Market: Segment Analysis, by Drug Class, 2018 - 2030 (USD Million)

  • 4.1 Infertility Drugs Market: Drug Class Movement Analysis
  • 4.2 Gonadotropins
    • 4.2.1 Gonadotropins Market, 2018 - 2030 (USD Million)
    • 4.2.2 Aromatase Inhibitors
      • 4.2.2.1 Aromatase Inhibitors Market, 2018 - 2030 (USD Million)
    • 4.2.3 Selective Estrogen Receptor Modulators (SERMs)
      • 4.2.3.1 Selective Estrogen Receptor Modulators (SERMs) Market, 2018 - 2030 (USD Million)
    • 4.2.4 Dopamine Agonists
      • 4.2.4.1 Dopamine Agonists Market, 2018 - 2030 (USD Million)
    • 4.2.5 Others
      • 4.2.5.1 Others Market, 2018 - 2030 (USD Million)

Chapter 5 Infertility Drugs Market: Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

  • 5.1 Infertility Drugs Market: Distribution Channel Movement Analysis
  • 5.2 Hospital Pharmacy
    • 5.2.1 Hospital Pharmacy Market, 2018 - 2030 (USD Million)
  • 5.3 Specialty & Retail Pharmacy
    • 5.3.1 Specialty & Retail Pharmacy Market, 2018 - 2030 (USD Million)
  • 5.4 Online Pharmacy
    • 5.4.1 Online Pharmacy Market, 2018 - 2030 (USD Million)

Chapter 6 Infertility Drugs Market: Segment Analysis, by End-User, 2018 - 2030 (USD Million)

  • 6.1 Infertility Drugs Market: End-User Movement Analysis
  • 6.2 Men
    • 6.2.1 Men Market, 2018 - 2030 (USD Million)
  • 6.3 Women
    • 6.3.1 Women Market, 2018 - 2030 (USD Million)

Chapter 7 Infertility Drugs Market: Regional Estimates and Trend Analysis

  • 7.1 North America
    • 7.1.1 SWOT Analysis:
      • 7.1.1.1 North America Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.1.2 U.S.
      • 7.1.2.1 Key Country Dynamics
      • 7.1.2.2 Target Disease Prevalence
      • 7.1.2.3 Competitive Scenario
      • 7.1.2.4 Regulatory Framework
      • 7.1.2.5 Reimbursement Scenario
      • 7.1.2.6 U.S. Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.1.3 Canada
      • 7.1.3.1 Key Country Dynamics
      • 7.1.3.2 Target Disease Prevalence
      • 7.1.3.3 Competitive Scenario
      • 7.1.3.4 Regulatory Framework
      • 7.1.3.5 Reimbursement Scenario
      • 7.1.3.6 Canada Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2 Europe
    • 7.2.1 SWOT Analysis:
      • 7.2.1.1 Europe Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2 UK
      • 7.2.2.1 Key Country Dynamics
      • 7.2.2.2 Target Disease Prevalence
      • 7.2.2.3 Competitive Scenario
      • 7.2.2.4 Regulatory Framework
      • 7.2.2.5 Reimbursement Scenario
      • 7.2.2.6 Prescription and Dispensing Scenario
      • 7.2.2.7 UK Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3 Germany
      • 7.2.3.1 Key Country Dynamics
      • 7.2.3.2 Target Disease Prevalence
      • 7.2.3.3 Competitive Scenario
      • 7.2.3.4 Regulatory Framework
      • 7.2.3.5 Reimbursement Scenario
      • 7.2.3.6 Germany Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4 France
      • 7.2.4.1 Key Country Dynamics
      • 7.2.4.2 Target Disease Prevalence
      • 7.2.4.3 Competitive Scenario
      • 7.2.4.4 Regulatory Framework
      • 7.2.4.5 Reimbursement Scenario
      • 7.2.4.6 France Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.5 Italy
      • 7.2.5.1 Key Country Dynamics
      • 7.2.5.2 Target Disease Prevalence
      • 7.2.5.3 Competitive Scenario
      • 7.2.5.4 Regulatory Framework
      • 7.2.5.5 Reimbursement Scenario
      • 7.2.5.6 Italy Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.6 Spain
      • 7.2.6.1 Key Country Dynamics
      • 7.2.6.2 Target Disease Prevalence
      • 7.2.6.3 Competitive Scenario
      • 7.2.6.4 Regulatory Framework
      • 7.2.6.5 Reimbursement Scenario
      • 7.2.6.6 Spain Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.7 Denmark
      • 7.2.7.1 Key Country Dynamics
      • 7.2.7.2 Target Disease Prevalence
      • 7.2.7.3 Competitive Scenario
      • 7.2.7.4 Regulatory Framework
      • 7.2.7.5 Reimbursement Scenario
      • 7.2.7.6 Denmark Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.8 Sweden
      • 7.2.8.1 Key Country Dynamics
      • 7.2.8.2 Target Disease Prevalence
      • 7.2.8.3 Competitive Scenario
      • 7.2.8.4 Regulatory Framework
      • 7.2.8.5 Reimbursement Scenario
      • 7.2.8.6 Sweden Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.9 Norway
      • 7.2.9.1 Key Country Dynamics
      • 7.2.9.2 Target Disease Prevalence
      • 7.2.9.3 Competitive Scenario
      • 7.2.9.4 Regulatory Framework
      • 7.2.9.5 Reimbursement Scenario
      • 7.2.9.6 Norway Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.9 Rest of Europe Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Asia Pacific
    • 7.3.1 SWOT Analysis:
      • 7.3.1.1 Asia Pacific Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2 Japan
      • 7.3.2.1 Key Country Dynamics
      • 7.3.2.2 Target Disease Prevalence
      • 7.3.2.3 Competitive Scenario
      • 7.3.2.4 Regulatory Framework
      • 7.3.2.5 Reimbursement Scenario
      • 7.3.2.6 Prescription and Dispensing Scenario
      • 7.3.2.7 Japan Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3 China
      • 7.3.3.1 Key Country Dynamics
      • 7.3.3.2 Target Disease Prevalence
      • 7.3.3.3 Competitive Scenario
      • 7.3.3.4 Regulatory Framework
      • 7.3.3.5 Reimbursement Scenario
      • 7.3.3.6 China Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4 India
      • 7.3.4.1 Key Country Dynamics
      • 7.3.4.2 Target Disease Prevalence
      • 7.3.4.3 Competitive Scenario
      • 7.3.4.4 Regulatory Framework
      • 7.3.4.5 Reimbursement Scenario
      • 7.3.4.6 India Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5 Australia
      • 7.3.5.1 Key Country Dynamics
      • 7.3.5.2 Target Disease Prevalence
      • 7.3.5.3 Competitive Scenario
      • 7.3.5.4 Regulatory Framework
      • 7.3.5.5 Reimbursement Scenario
      • 7.3.5.6 Australia Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6 South Korea
      • 7.3.6.1 Key Country Dynamics
      • 7.3.6.2 Target Disease Prevalence
      • 7.3.6.3 Competitive Scenario
      • 7.3.6.4 Regulatory Framework
      • 7.3.6.5 Reimbursement Scenario
      • 7.3.6.6 South Korea Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7 Thailand
      • 7.3.7.1 Key Country Dynamics
      • 7.3.7.2 Target Disease Prevalence
      • 7.3.7.3 Competitive Scenario
      • 7.3.7.4 Regulatory Framework
      • 7.3.7.5 Reimbursement Scenario
      • 7.3.7.6 Thailand Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8 Rest of APAC Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Latin America
    • 7.4.1 SWOT Analysis:
      • 7.4.1.1 Latin America Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2 Brazil
      • 7.4.2.1 Key Country Dynamics
      • 7.4.2.2 Target Disease Prevalence
      • 7.4.2.3 Competitive Scenario
      • 7.4.2.4 Regulatory Framework
      • 7.4.2.5 Reimbursement Scenario
      • 7.4.2.6 Prescription and Dispensing Scenario
      • 7.4.2.7 Brazil Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3 Mexico
      • 7.4.3.1 Key Country Dynamics
      • 7.4.3.2 Target Disease Prevalence
      • 7.4.3.3 Competitive Scenario
      • 7.4.3.4 Regulatory Framework
      • 7.4.3.5 Reimbursement Scenario
      • 7.4.3.6 Mexico Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4 Argentina
      • 7.4.4.1 Key Country Dynamics
      • 7.4.4.2 Target Disease Prevalence
      • 7.4.4.3 Competitive Scenario
      • 7.4.4.4 Regulatory Framework
      • 7.4.4.5 Reimbursement Scenario
      • 7.4.4.6 Argentina Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Rest of Latin America Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Middle East & Africa (MEA)
    • 7.5.1 SWOT Analysis:
      • 7.5.1.1 MEA Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2 South Africa
      • 7.5.2.1 Key Country Dynamics
      • 7.5.2.2 Target Disease Prevalence
      • 7.5.2.3 Competitive Scenario
      • 7.5.2.4 Regulatory Framework
      • 7.5.2.5 Reimbursement Scenario
      • 7.5.2.6 Prescription and Dispensing Scenario
      • 7.5.2.7 South Africa Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3 Saudi Arabia
      • 7.5.3.1 Key Country Dynamics
      • 7.5.3.2 Target Disease Prevalence
      • 7.5.3.3 Competitive Scenario
      • 7.5.3.4 Regulatory Framework
      • 7.5.3.5 Reimbursement Scenario
      • 7.5.3.6 Saudi Arabia Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4 UAE
      • 7.5.4.1 Key Country Dynamics
      • 7.5.4.2 Target Disease Prevalence
      • 7.5.4.3 Competitive Scenario
      • 7.5.4.4 Regulatory Framework
      • 7.5.4.5 Reimbursement Scenario
      • 7.5.4.6 UAE Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5 Kuwait
      • 7.5.5.1 Key Country Dynamics
      • 7.5.5.2 Target Disease Prevalence
      • 7.5.5.3 Competitive Scenario
      • 7.5.5.4 Regulatory Framework
      • 7.5.5.5 Reimbursement Scenario
      • 7.5.5.6 Kuwait Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6 Rest of MEA Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8 Infertility Drugs Market: Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants
    • 8.1.1 New Product Launch
    • 8.1.2 Merger and Acquisition
    • 8.1.3 Licensing Agreements
    • 8.1.4 Conferences and Campaigns
  • 8.2 Company Categorization
    • 8.2.1 Innovators
    • 8.2.2 Market Leaders
  • 8.3 Vendor Landscape
    • 8.3.1 List of Key Distributors and Channel Partners
    • 8.3.2 Key Customers
  • 8.4 Public Companies
    • 8.4.1 Key Company Market Share Analysis, 2021
    • 8.4.2 Company Market Position Analysis
    • 8.4.3 Heat Map Analysis
    • 8.4.4 Competitive Dashboard Analysis
      • 8.4.4.1 Market Differentiators
  • 8.5 Private Companies
    • 8.5.1 List of Key Emerging Companies
    • 8.5.2 Regional Network Map
  • 8.6 Company Profiles
      • 8.6.1.Bayer AG
      • 8.6.1.1 Company Overview
      • 8.6.1.2 Financial Performance
      • 8.6.1.3 Product Benchmarking
      • 8.6.1.4 Strategic Initiatives
    • 8.6.2 Novartis AG
      • 8.6.2.1 Company Overview
      • 8.6.2.2 Financial Performance
      • 8.6.2.3 Product Benchmarking
      • 8.6.2.4 Strategic Initiatives
    • 8.6.3 Merck & Co., Inc.
      • 8.6.3.1 Company Overview
      • 8.6.3.2 Financial Performance
      • 8.6.3.3 Product Benchmarking
      • 8.6.3.4 Strategic Initiatives
    • 8.6.4 Ferring B.V.
      • 8.6.4.1 Company Overview
      • 8.6.4.2 Financial Performance
      • 8.6.4.3 Product Benchmarking
      • 8.6.4.4 Strategic Initiatives
    • 8.6.5 Pfizer Inc.
      • 8.6.5.1 Company Overview
      • 8.6.5.2 Financial Performance
      • 8.6.5.3 Product Benchmarking
      • 8.6.5.4 Strategic Initiatives
    • 8.6.6 Mankind Pharma
      • 8.6.6.1 Company Overview
      • 8.6.6.2 Financial Performance
      • 8.6.6.3 Product Benchmarking
      • 8.6.6.4 Strategic Initiatives
    • 8.6.7 Teva Pharmaceutical Industries LTD.
      • 8.6.7.1 Company Overview
      • 8.6.7.2 Financial Performance
      • 8.6.7.3 Product Benchmarking
      • 8.6.7.4 Strategic Initiatives
    • 8.6.8 Sanofi
      • 8.6.8.1 Company Overview
      • 8.6.8.2 Financial Performance
      • 8.6.8.3 Product Benchmarking
      • 8.6.8.4 Strategic Initiatives
    • 8.6.9 Abbott
      • 8.6.8.1 Company Overview
      • 8.6.9.2 Financial Performance
      • 8.6.9.3 Product Benchmarking
      • 8.6.9.4 Strategic Initiatives
    • 8.6.10 Organon Group of Countries
      • 8.6.10.1 Company Overview
      • 8.6.10.2 Product Benchmarking
      • 8.6.10.3 Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Regulatory Framework
  • Table 4 Global Infertility Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 6 Global Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 7 Global Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 8 North America Infertility Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 9 North America Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 10 North America Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 11 North America Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 12 U.S. Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 13 U.S. Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 14 U.S. Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 15 Canada Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 16 Canada Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 17 Canada Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 18 Europe Infertility Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 19 Europe Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 20 Europe Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 21 Europe Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 22 Germany Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 23 Germany Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 24 Germany Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 UK Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 26 UK Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 27 UK Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 France Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 29 France Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 30 France Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 31 Italy Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 32 Italy Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 33 Italy Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 Spain Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 35 Spain Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 36 Spain Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 37 Denmark Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 38 Denmark Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 39 Denmark Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 Sweden Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 41 Sweden Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 42 Sweden Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 Norway Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 44 Norway Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 45 Norway Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Infertility Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 50 Japan Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 51 Japan Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 52 Japan Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 53 China Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 54 China Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 55 China Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 India Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 57 India Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 58 India Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 59 South Korea Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 60 South Korea Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 61 South Korea Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 62 Australia Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 63 Australia Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 64 Australia Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 65 Thailand Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 66 Thailand Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 67 Thailand Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 68 Latin America Infertility Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 69 Latin America Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 70 Latin America Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 71 Latin America Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 72 Brazil Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 73 Brazil Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 74 Brazil Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 75 Mexico Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 76 Mexico Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 77 Mexico Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 78 Argentina Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 79 Argentina Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 80 Argentina Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Infertility Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 84 Middle East & Africa Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 85 Saudi Arabia Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 88 South Africa Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 89 South Africa Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 90 South Africa Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 91 UAE Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 92 UAE Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 93 UAE Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Infertility Drugs Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Data Triangulation Techniques
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-Chain-Based Sizing & Forecasting
  • Fig. 7 QFD Modeling for Market Share Assessment
  • Fig. 8 Market Formulation & Validation
  • Fig. 9 Commodity Flow Analysis
  • Fig. 10 Market Snapshot (2022) (USD Million)
  • Fig. 11 Segment Snapshot (2022) (USD Million)
  • Fig. 12 Segment Snapshot (2022) (USD Million)
  • Fig. 13 Competitive Snapshot
  • Fig. 14 Penetration and Growth Prospect Mapping
  • Fig. 15 Infertility Drugs Market Driver Impact
  • Fig. 16 Infertility Drugs Market Restraint Impact
  • Fig. 17 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
  • Fig. 18 Porter's Five Forces Analysis
  • Fig. 19 Infertility Drugs Market: Drug Class Outlook and Key Takeaways
  • Fig. 20 Infertility Drugs Market: Drug Class Movement Analysis
  • Fig. 21 Gonadotropins Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Aromatase Inhibitors Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Selective Estrogen Receptor Modulators (SERMs) Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Dopamine Agonists Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Others Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Infertility Drugs Market: Distribution Channe Outlook and Key Takeaways
  • Fig. 27 Infertility Drugs Market: Distribution Channel Movement Analysis
  • Fig. 28 Hospital Pharmacy Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Specialty & Retail Pharmacy Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Online Pharmacy Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Infertility Drugs Market: End-User Outlook and Key Takeaways
  • Fig. 32 Infertility Drugs Market: End-User Movement Analysis
  • Fig. 33 Men Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Women Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Regional Marketplace: Key Takeaways
  • Fig. 36 North America: SWOT analysis
  • Fig. 37 North America Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. Key Country Dynamics
  • Fig. 39 U.S. Target Disease Prevalence
  • Fig. 40 U.S. Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Canada Key Country Dynamics
  • Fig. 42 Canada Target Disease Prevalence
  • Fig. 43 Canada Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Europe: SWOT analysis
  • Fig. 45 Europe Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Germany Key Country Dynamics
  • Fig. 47 Germany Target Disease Prevalence
  • Fig. 48 Germany Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 UK Key Country Dynamics
  • Fig. 50 UK Target Disease Prevalence
  • Fig. 51 UK Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 France Key Country Dynamics
  • Fig. 53 France Target Disease Prevalence
  • Fig. 54 France Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Italy Key Country Dynamics
  • Fig. 56 Italy Target Disease Prevalence
  • Fig. 57 Italy Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Spain Key Country Dynamics
  • Fig. 59 Spain Target Disease Prevalence
  • Fig. 60 Spain Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Denmark Key Country Dynamics
  • Fig. 62 Denmark Target Disease Prevalence
  • Fig. 63 Denmark Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Sweden Key Country Dynamics
  • Fig. 65 Sweden Target Disease Prevalence
  • Fig. 66 Sweden Infertility Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Norway Key Country Dynamics
  • Fig. 68 Norway Target Disease Prevalence
  • Fig. 69 Norway Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Rest of Europe Infertility Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Asia Pacific: SWOT Analysis
  • Fig. 72 Asia Pacific Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Japan Key Country Dynamics
  • Fig. 74 Japan Target Disease Prevalence
  • Fig. 75 Japan Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 China Key Country Dynamics
  • Fig. 77 China Target Disease Prevalence
  • Fig. 78 China Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 India Key Country Dynamics
  • Fig. 80 India Target Disease Prevalence
  • Fig. 81 India Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Australia Key Country Dynamics
  • Fig. 83 Australia Target Disease Prevalence
  • Fig. 84 Australia Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 South Korea Key Country Dynamics
  • Fig. 86 South Korea Target Disease Prevalence
  • Fig. 87 South Korea Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Thailand Key Country Dynamics
  • Fig. 89 Thailand Target Disease Prevalence
  • Fig. 90 Thailand Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Rest of APAC Infertility Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Latin America (LATAM): SWOT Analysis
  • Fig. 93 Latin America Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Brazil Key Country Dynamics
  • Fig. 95 Brazil Target Disease Prevalence
  • Fig. 96 Brazil Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Mexico Key Country Dynamics
  • Fig. 98 Mexico Target Disease Prevalence
  • Fig. 99 Mexico Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 Argentina Key Country Dynamics
  • Fig. 101 Argentina Target Disease Prevalence
  • Fig. 102 Argentina Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Rest of LATAM Infertility Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 104 Middle East & Africa (MEA): SWOT Analysis
  • Fig. 105 Middle East & Africa (MEA) Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 South Africa Key Country Dynamics
  • Fig. 107 Target Disease Prevalence
  • Fig. 108 South Africa Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 Saudi Arabia Key country dynamics
  • Fig. 110 Saudi Arabia Target Disease Prevalence
  • Fig. 111 Saudi Arabia Infertility Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 112 UAE Key Country Dynamics
  • Fig. 113 UAE Target Disease Prevalence
  • Fig. 114 UAE Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 115 Kuwait Key Country Dynamics
  • Fig. 116 Kuwait Target Disease Prevalence
  • Fig. 117 Kuwait Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 118 Rest of MEA Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 119 Heat Map Analysis
  • Fig. 120 Strategic Framework